News Interim report for 1H 2023 Please read the full announcement in PDF Attachment 2023_54_Q22023_CompanyAnnouncement Continue Reading Previous Novartis remibrutinib Phase III trials met their primary endpoints and showed rapid symptom control in chronic spontaneous urticariaNext Novozymes delivers results within expectations in the first half of 2023 and narrows the full year outlook Related Stories News Acceleware Awarded $2 Million in Non-Dilutive Funding News Applied Atomics Emerges from Stealth with More Than $500 Million in Demand Commitments to Build the Star Reacher Network, the Next Infrastructure Layer of the Space Economy News Grid My Business Earns G2 High Performer and Fastest Implementation Badges in Summer 2026 News CEO.CA’s Inside the Boardroom: Talisker Resources Updates Market with Doubled Gold Resource at Bralorne Project News The FUTR Corporation to Host Investor Webinar: “One Million Plans: How FUTR Planning Accelerates the Agent App” News American Nortel Provides India Operations Update: Technology Infrastructure and Data Systems Positioned to Support Continued Sales Growth